Join Lipocine for a virtual KOL event featuring Frank Greenway, MD (Chief Medical Officer at Pennington Biomedical Research Center), who will discuss the unmet needs and current treatment landscape in obesity management with a focus on fat loss and lean muscle mass preservation for patients on incretin therapies.

The webinar will also review positive data from the Phase 2 study of LPCN 2401, an oral proprietary androgen receptor agonist, which showed significant improvements in body composition.

The data support the potential for LPCN 2401 to be used as an adjunct with incretin mimetics (GLP-1/GIP agonists) or as a monotherapy post incretin mimetic discontinuation.

A live question and answer session will follow the formal presentation.